Diabetes Archives

Study reveals hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes. John Buse, MD, PhD, director of UNC’s Diabetes Care Center, is lead author.

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and/or chronic kidney disease.

Researchers at the UNC School of Medicine have proven that antibiotic-resistant strains of a harmful bacteria thrive in a diabetic infection environment.

Randomized, placebo-controlled trial finds that low-dose semaglutide reduces amount of alcohol consumption, alcohol cravings, and heavy drinking days. Reductions in cigarettes per day were also seen.

Nina Jain, MD, MBA, professor of pediatric endocrinology, and Ali Calikoglu, MD, retired professor of pediatrics, both at the UNC School of Medicine, played a pivotal role in getting this therapy to the bedside, from assisting with clinical trials to the infusion of the first pediatric patient in North Carolina at UNC Children’s.

Brooke Matson, Jeremy Meier, Brittany Raffa, and Shivani Sud will receive support from the UNC School of Medicine Physician Scientists Training Program to cultivate their careers as translational clinical scientists.

A woman with blonde hair and a white lab coat stands with hands in her pockets

A research study named Early Check has screened 1,000 newborns after birth in an effort to help identify rare conditions early, provide treatment, give parents educational information, and connect families with specialists throughout the state of North Carolina.

Springer recently released "Chronic Illness Care, Principles and Practice," edited by UNC Family Medicine's Timothy P. Daaleman, DO, MPH, and Margaret R. Helton, MD. Faculty members in the Department of Family Medicine, faculty across the UNC-Chapel Hill campus, and other national and international experts wrote the textbook.

A multicenter, randomized, phase 3b trial, done in collaboration with a UNC School of Medicine researcher, found that once-daily oral semaglutide taken at higher doses of 25mg and 50mg improved regulation of blood sugar levels and weight loss compared to the standard 14 mg dose.

The study, which was conducted at UNC-Chapel Hill between 2016 and 2022, concluded that metformin use did not reduce risks for adverse neonatal outcomes in pregnancies with type 2 diabetes. The study findings were reported at the annual meeting of the Society for Maternal Fetal Medicine in February.

11-year-old Izzy Dixon is sharing her story on how she is managing her Type 1 diabetes at a young age. Hear her story and how experts at UNC Children's guided her on her journey to wellness.

This nationwide clinical trial funded through the National Institutes of Health including participation from patients at the UNC Diabetes Center, led by John Buse, MD, PhD.

Category: Diabetes

Research Shows Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

Study Finds Oral Semaglutide Vastly Reduces Heart Attacks, Strokes

Diabetes Can Drive the Evolution of Antibiotic Resistance

Semaglutide Shows Promise in Reducing Cravings for Alcohol, Heavy Drinking

A New Therapy to Prevent or Delay Type 1 Diabetes Now Available at UNC Children’s Hospital

Four Scholars Named to Physician Scientist Training Program

A Newborn Genetic Screening Study Reaches New Milestone

UNC Department of Family Medicine Authors Second Edition of Chronic Illness Care Textbook

Higher Doses of Oral Semaglutide Improves Blood Sugar Control and Weight Loss

Metformin Combined with Insulin Does Not Reduce Pregnancy Outcome Risks Compared to Placebo

Living with Type 1 Diabetes: Izzy Shares Her Story

Bionic Pancreas Improves Type 1 Diabetes Management Compared to Standard Insulin Delivery Methods